Table of Contents
ISRN Nursing
Volume 2012, Article ID 454898, 7 pages
Research Article

Retrospective Study of Japanese Patients with Schizophrenia Treated with Aripiprazole

1Department of Nursing, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima 770-8509, Japan
2Christine E. Lynn College of Nursing, Florida Atlantic University, Boca Raton, FL 33431, USA
3Department of Psychiatry, Mifune Hospital, Kagawa 763-0073, Japan

Received 21 May 2012; Accepted 5 July 2012

Academic Editors: A. Green and R. Schreiber

Copyright © 2012 Tetsuya Tanioka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Aim. The purpose of this retrospective study was to evaluate changes in clinical indicators which influence the quality of life (QOL) of patients with schizophrenia treated by antipsychotic therapy before and after switching to aripiprazole. Methods. A retrospective chart review of 27 patients diagnosed with schizophrenia and who were switched from one antipsychotic to aripiprazole was performed. Clinical indicators about the daily dosage of antipsychotics and antiparkinsonian drugs, psychiatric condition, and glucose/lipid metabolism, clinical evaluation by nursing observation were used to measure the responsiveness of subjects to aripiprazole. Results. Of the 27 subjects, 14 responded to the switch to aripiprazole with significant improvement of the Brief Psychiatric Rating Scale (BPRS) score ( 𝑃 = 0 . 0 4 ), significant decrease in dosage of antipsychotics in 71% of patients ( 𝑃 = 0 . 0 3 ), and tendency toward reduction in dosage of antiparkinsonian drugs ( 𝑃 = 0 . 0 7 ) and body mass index (BMI) ( 𝑃 = 0 . 0 6 ). However, 8 of 27 subjects had a significant increase in lipid levels after switching to aripiprazole ( 𝑃 = 0 . 0 1 ). Conclusion. QOL for subjects who responded to the switch to aripiprazole improved as indicated by lower doses of antipsychotic and antiparkinson medications, improvement in BPRS score, and a decrease in BMI. Results indicate little influence on patient's QOL.